Analytical testing confirms 99.2 % purity for BPC-157 and greater than 99.8 % purity for TB-500 , with assay content verified at 7.36 mg and 6.11 mg respectively
In response to these limitations, CQDs have emerged as promising candidates for central nervous system (CNS) delivery, owing to their ultrasmall size, tuneable surface chemistry, and potential to engage endogenous transport mechanisms [141]
Patch testing is strongly recommended, especially for products targeting sensitive skin or compromised skin barriers, to identify any potential sensitivities before widespread use
Mohamed M, Thio J, Thomas RS, Phillips J
*Dependent on the extent of renal dysfunction and age of the patient